Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 725Lymphoma, Non-Hodgkin 659Precursor Cell Lymphoblastic Leukemia-Lymphoma 585Leukemia, Lymphocytic, Chronic, B-Cell 555Lymphoma, Large B-Cell, Diffuse 440Lymphoma, Follicular 419Lymphoma, Mantle-Cell 345Burkitt Lymphoma 306Leukemia 304Leukemia, Myeloid, Acute 298Hodgkin Disease 294Lymphoma, B-Cell 281Lymphoma, B-Cell, Marginal Zone 267Recurrence 246Multiple Myeloma 205Neoplasms 200Myelodysplastic Syndromes 171Lymphoma, T-Cell, Cutaneous 171Lymphoma, Large-Cell, Immunoblastic 160Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 159Waldenstrom Macroglobulinemia 146Lymphoma, Large-Cell, Anaplastic 142Mycosis Fungoides 132Sezary Syndrome 119Immunoblastic Lymphadenopathy 108Blast Crisis 92Hematologic Neoplasms 91Lymphoma, T-Cell, Peripheral 86Leukemia, Myelogenous, Chronic, BCR-ABL Positive 86Lymphoma, T-Cell 82

Interventions

TAK-659 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Advanced Solid Neoplasms × Lymphoid × Clear all
NCT03338881 2023-02-08

A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participants With Advanced Solid Tumor and/or Lymphoma Malignancies

Calithera Biosciences, Inc

Phase 1 Withdrawn
Lymphoid

Advanced Solid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡